Keyphrases
Junctional Adhesion Molecule
100%
Multiple Myeloma
100%
Oncolytic Adenovirus
100%
Reolysin
85%
Reovirus
42%
Induced Cell Death
28%
Relapsed Disease
28%
High Mortality Rate
14%
Clinical Trials
14%
Bortezomib
14%
New Agents
14%
Myeloma Cells
14%
Cancer Therapy
14%
Solid Tumors
14%
Drug Resistance
14%
Molecular Features
14%
Selective Effect
14%
Hematological Malignancies
14%
Acquired Resistance
14%
Antineoplastic Agents
14%
Primary Cells
14%
Myeloma Therapy
14%
Predictive Biomarker
14%
Relapsed or Refractory multiple Myeloma
14%
Precision Approach
14%
Medicine and Dentistry
Junctional Adhesion Molecule A
100%
Multiple Myeloma
100%
Oncolytic Reovirus
100%
Pelareorep
85%
Reoviridae
42%
Disease
28%
Cell Death
28%
Mortality Rate
14%
Clinical Trial
14%
Receptor
14%
Bortezomib
14%
Cancer Therapy
14%
Solid Malignant Neoplasm
14%
Biological Marker
14%
Drug Resistance
14%
Hematologic Malignancy
14%
Multiple Myeloma Cell Line
14%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Junctional Adhesion Molecule A
100%
Oncolytic Reovirus
100%
Pelareorep
75%
Reoviridae
37%
Disease
25%
Malignant Neoplasm
12%
Receptor
12%
Clinical Trial
12%
Bortezomib
12%
Mortality Rate
12%
Biological Marker
12%
Solid Malignant Neoplasm
12%
Drug Resistance
12%
Hematologic Malignancy
12%
Biochemistry, Genetics and Molecular Biology
Cell Adhesion Molecule
100%
Reoviridae
100%
Cell Death
28%
Eicosanoid Receptor
14%
Mortality Rate
14%
Clinical Trial
14%
Drug Resistance
14%
Primary Cell
14%
Immunology and Microbiology
Junctional Adhesion Molecule A
100%